ARTICLES

InProTher science

The InProTher approach is based upon the research from the founder and CSO Peter Holst and the CTO Anne-Marie Andersson. Key in the anti-cancer approach is the Virus-Like-Vaccine technology delivered by hAd19a/64 vaccine vectors, whereas licenses for the Invariant Chain technology within HIV and HPV vaccines are the cornerstone in the infectious disease program.

2018

Virus-like-vaccines against HIV. / Andersson, Anne Marie C.; Schwerdtfeger, Melanie; Holst, Peter J.

In: Vaccines, Vol. 6, No. 1, 10, 03.2018.

Replication deficient human adenovirus vector serotype 19a/64 : Immunogenicity in mice and female cynomolgus macaques. / Ragonnaud, Emeline; Schroedel, Silke; Mariya, Silmi; Iskandriati, Diah; Pamungkas, Joko; Fougeroux, Cyrielle; Daradoumis, Joana; Thomsen, Allan R.; Neukirch, Lasse; Ruzsics, Zsolt; Salomon, Michael; Thirion, Christian; Holst, Peter J.

In: Vaccine, Vol. 36, No. 41, 2018, p. 6212-6222.

2017

Novel adenovirus encoded virus-like particles displaying the placental malaria associated VAR2CSA antigen. / Andersson, Anne-Marie C; dos Santos Marques Resende, Mafalda; Salanti, Ali; Nielsen, Morten A; Holst, Peter J.

In: Vaccine, Vol. 35, No. 8, 22.02.2017, p. 1140-1147.

Therapeutic vaccine against primate papillomavirus infections of the cervix. / Ragonnaud, Emeline; Andersson, Anne-Marie C; Mariya, Silmi; Pedersen, Anders G; Burk, Robert D; Folgori, Antonella; Colloca, Stefano; Cortese, Riccardo; Nicosia, Alfredo; Pamungkas, Joko; Iskandriati, Diah; Holst, Peter J.

In: Journal of Immunotherapy, Vol. 40, No. 2, 07.02.2017, p. 51-61.

Mucosal vaccination with heterologous viral vectored vaccine targeting subdominant SIV accessory antigens strongly inhibits early viral replication. / Xu, Huanbin; Andersson, Anne-Marie Carola; Ragonnaud, Emeline; Boilesen, Ditte ; Tolver, Anders; Jensen, Benjamin Anderschou Holbech; Blanchard, James L; Nicosia, Alfredo; Folgori, Antonella; Colloca, Stefano; Cortese, Riccardo; Thomsen, Allan Randrup; Christensen, Jan Pravsgaard; Veazey, Ronald S.; Holst, Peter Johannes.

In: EBioMedicine, Vol. 18, 04.2017, p. 204–215.

2016

Effect of HIV-1 envelope cytoplasmic tail on adenovirus primed virus encoded virus-like particle immunizations. / Andersson, Anne Marie C; Ragonnaud, Emeline; Seaton, Kelly E.; Sawant, Sheetal; Folgori, Antonella; Colloca, Stefano; Labranche, Celia; Montefiori, David C.; Tomaras, Georgia D.; Holst, Peter J.

In: Vaccine, Vol. 34, No. 44, 17.10.2016, p. 5344-5351.

Oncofetal chondroitin sulfate glycosaminoglycans are key players in integrin signaling and tumor cell motility. / Clausen, Thomas Mandel; Bento Ayres Pereira, Marina Maria; Al Nakouzi, Nader; Oo, Htoo Zarni; Agerbæk, Mette Ø; Lee, Sherry; Ørum-Madsen, Maj Sofie; Kristensen, Anders Riis; El-Naggar, Amal; Grandgenett, Paul M; Grem, Jean L; Hollingsworth, Michael A; Holst, Peter J; Theander, Thor; Sorensen, Poul H; Daugaard, Mads; Salanti, Ali.

In: Molecular Cancer Research, Vol. 14, No. 12, 12.2016, p. 1288-1299.

Published Patents

1: “A Nucleotide vaccine” (Patent WO2007062656A3)

2: Priming an immune response (WO2010057501A1)

3: IMPROVED VACCINES” UK as 1614387.7 on 23rd of August 2016*

4: “Improved li vaccine adjuvant” UK as 1704417.3 on 20th of March 2017

5: “A VACCINE FOR USE IN THE PROPHYLAXIS AND/OR TREATMENT OF A DISEASE” DK as PA 201770659 on September 1st , 2017

  RESEARCH IN YOUR INBOX

– Always be updated on our research. 

WordPress Theme built by Shufflehound.